Przejdź do treści
W Polsce: Wkrótce rekrutacjaNa świecie: Rekrutacja wkrótceFaza IIIPolskaBośnia i HercegowinaBułgariaChorwacjaFrancjaGrecjaGruzjaIndieLitwaMacedonia Płn.+4

Zapalenie płuc: badanie kliniczne fazy III

Tytuł w rejestrze: Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

Najważniejsze informacje

Choroba
Zapalenie płuc (Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP))
Faza
Faza III
Status w Polsce
Wkrótce rekrutacjarejestr nie podaje osobnego stanu dla Polski, pokazujemy stan całego badania
Status na świecie
Rekrutacja wkrótcestan całego badania w rejestrze
Wiek uczestników
18-90 lat
Płeć
kobiety i mężczyźni
Planowana liczba uczestników
łącznie 324
Sponsor
Wockhardt
Terminy (planowane)
28 października 2026 - 31 grudnia 2027
Kraje
PolskaBośnia i HercegowinaBułgariaChorwacjaFrancjaGrecjaGruzjaIndieLitwaMacedonia Płn.MoldovaRumuniaSerbiaWłochy 14: Bośnia i Hercegowina, Bułgaria, Chorwacja, Francja, Grecja, Gruzja, Indie, Litwa, Macedonia Płn., Moldova, Polska, Rumunia…
Numer w rejestrze
NCT07885891 (ClinicalTrials.gov)

Gdzie prowadzone jest badanie

Ośrodki prowadzące badanie w Polsce (4), alfabetycznie według miejscowości:

Zapytaj o udział w badaniu

Najszybciej: porozmawiaj z naszym doradcą ds. badań.

Zadzwoń do naszego specjalisty+48 664 930 800pon-pt: 9:00 - 18:00

albo zostaw numer, oddzwonimy:

O Twoim zdrowiu porozmawiamy dopiero przez telefon, po Twojej zgodzie. W formularzu nie podajesz takich informacji.

rekrutuje wkrótce nie rekrutuje lub brak danych

Kliknij kropkę, żeby zobaczyć ośrodki w mieście.

Więcej badań w tych miastach:

Stan rekrutacji pochodzi z rejestrów badań i może się zmienić szybciej, niż zaktualizuje go sponsor. Nasz doradca sprawdzi aktualny stan w wybranym ośrodku. Nie publikujemy nazwisk lekarzy ani ich danych kontaktowych.

Cel badania

Opis z rejestru (w języku angielskim):

This is a Phase 3, randomized, double-blind, multicenter, comparative study evaluating cefepime-zidebactam (FEP-ZID) versus ceftazidime-avibactam (CAZ-AVI) with or without colistin in the treatment of adults with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP). Trial participants will be randomized in a 1:1 ratio to receive either FEP-ZID or CAZ-AVI with or without colistin for 7 to 14 days. Colistin will be added to the CAZ-AVI regimen (or matching saline to the FEP-ZID regimen, to maintain blinding) for participants with a baseline pathogen presumed or confirmed to be CAZ-AVI-resistant. All trial participants will also receive linezolid for coverage of methicillin-resistant staphylococci for at least the first 3 days of treatment.

The primary objectives are to assess 14-day all-cause mortality between treatment groups and to assess the safety and tolerability of FEP-ZID relative to CAZ-AVI with or without colistin. Secondary objectives include 28-day all-cause mortality, clinical and microbiological outcomes at End-of-Treatment (EOT) and Test-of-Cure (TOC), sustained clinical cure at Late Follow-up (LFU), superinfection and new infection rates, and pharmacokinetic (PK) characterization of FEP and ZID.

Leczenie w badaniu

Lek / interwencjaRolaPostać, podanie
Cefepime-ZidebactamLek
Ceftazidime-avibactam with or without ColistinLek

Kryteria udziału

Kryteria w języku angielskim, tak jak w rejestrze.

Kryteria włączenia kto może wziąć udział (23)

  1. Male or female ≥18 years of age.
  2. Provide signed written informed consent prior to any study specific procedures. A legally acceptable representative may provide consent provided this is permitted by national law and ethical considerations as well as institution-specific guidelines (proxy consent). In participants in clinical course compatible with an emergency situation and not able to provide consent while a legally acceptable representative is not available, a deferred consent framework for emergency research may be applied if permitted by national law and ethical considerations as well as institution-specific guidelines.
  3. Have at least one of the following new-onset or worsening signs within 24 hours prior to randomization:
  4. Fever (oral, tympanic, temporal, or rectal temperature >38 °C [>100.4 °F])
  5. Hypothermia (rectal/core temperature <35 °C [<95.2 °F])
  6. White blood cell (WBC) count >10,000 cells/mm3
  7. WBC count of <4,500 cells/mm3
  8. Bandemia (immature neutrophils) on a WBC count of >15%
  9. Meet ALL the following clinical criteria for either: A. VABP:
  10. Receiving continuous mechanical ventilation ≥48 hours prior to the onset of signs and symptoms of pneumonia.
  11. New or worsening infiltrate consistent with pneumonia on chest X-ray or chest computed tomography (CT) obtained at least 48 hours after starting mechanical ventilation.
  12. Required acute changes in ventilator support to improve oxygenation with worsening ratio of the partial pressure of oxygen in arterial blood to the inspired oxygen fraction or needed changes in the amount of positive end-expiratory pressure. B. HABP:
  13. Hospitalized for more than 48 hours prior to the onset of signs and symptoms of pneumonia (or had a prior hospital admission >48 hours if discharged within the last 7 days).
  14. New or worsening infiltrate consistent with pneumonia on X-ray or chest CT obtained at least 48 hours or more after hospital admission.
  15. New onset or acute worsening pulmonary symptoms or signs, such as cough, dyspnea, tachypnea, (e.g., respiratory rate greater than 25 breaths per minute), hypoxemia, expectorated sputum production, and/or requirement for mechanical ventilation. 5. If a female of childbearing potential, must have a negative urine or serum pregnancy test (β-human chorionic gonadotropin) during their hospitalization and must agree to use one of the following highly effective methods of contraception through TOC:
  16. Surgical sterilization (defined as bilateral oophorectomy or bilateral salpingectomy, but excluding bilateral tubal occlusion)
  17. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal)
  18. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable)
  19. Intrauterine device
  20. Intrauterine hormone-releasing system
  21. Sexual intercourse with only vasectomized partners, or
  22. Abstinence, defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the trial participant
  23. Post-menopausal (as defined in the note below) Note: a female is considered to be of childbearing potential unless post-menopausal for more than 1 year of spontaneous amenorrhea or permanently surgically sterilized (bilateral oophorectomy, salpingectomy, hysterectomy, tubal ligation). A high follicle stimulation hormone level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. 6.If male, trial participant must agree to use an acceptable barrier method of birth control (i.e., condom) with female partner(s) of childbearing potential who are using one of the contraceptive methods described above in Inclusion Criterion 5, and must not donate sperm from Screening through TOC.

Kryteria wyłączenia kto nie może wziąć udziału (33)

  1. History of serious or significant hypersensitivity or allergic reaction (e.g., anaphylaxis, urticaria, other significant reaction) to any β-lactam antibiotic or to the excipient L-arginine; avibactam or avibactam-containing-product; linezolid; or colistin.
  2. Current pneumonia due to Stenotrophomonas or Burkholderia species identified on culture prior to randomization.
  3. Known or suspected community-acquired, viral, fungal (including Pnuemocystis jirovecii), mycobacterial (including tuberculous), or parasitic pneumonia.
  4. Diagnosed or suspected to have atypical pneumonia (including Legionella pneumophilia) or a positive test result on the BPP for an atypical organism.
  5. Current pneumonia known or suspected to be caused by an organism that is resistant to FEP-ZID or to both CAZ-AVI and colistin.
  6. Diagnosed with COVID-19 or positive test for SARS-CoV-2 virus within the past 2 weeks.
  7. Any of the following conditions or diagnoses:
  8. Cystic fibrosis or similar conditions (e.g., non-cystic fibrosis bronchiectasis)
  9. Lung abscess
  10. Pleural empyema
  11. Lung cancer or metastases to the lungs or other known causes of pulmonary obstruction
  12. Penetrating chest trauma
  13. Definitive diagnosis of aspiration pneumonia
  14. Any other infection outside of the lung that requires systemic antibacterial therapy
  15. Current treatment with a monoamine oxidase inhibitor (MAOI) or having received a MAOI within the past 2 weeks prior to randomization, or need for such treatment during the study treatment period.
  16. Current receipt of curariform muscle relaxants (e.g., tubocurarine) or other drugs potentiating the neuromuscular blocking effect (e.g., ether, succinylcholine, gallamine, decamethonium and sodium citrate), or need for such treatment during the study treatment period.
  17. Receipt of CAZ-AVI or FEP-ZID within 30 days prior to enrolment for treatment of any infection.
  18. Receipt of potentially effective systemic or inhaled antibacterial therapy for more than 48 hours within 72 hours prior to randomization, with the exception of either of the following: * Receipt of >48 hours of prior antibiotic therapy and in the investigator's opinion, failed that prior antibiotic therapy (i.e., worsening signs and symptoms) or * Documented to have a gram-negative pathogen that is non-susceptible to the prior therapy administered for the pneumonia
  19. Pneumonia caused by sole gram-positive pathogen(s) if known based on culture report or BPP result.
  20. Expected survival <72 hours or having a "do not resuscitate" order or any life-threatening condition other than index pneumonia, due to which the trial participant is likely not to survive the study period.
  21. APACHE II score of >30.
  22. History of epilepsy or seizure disorder requiring current treatment with anti-seizure medication.
  23. Women who are pregnant or nursing.
  24. Participants CRRT (e.g., continuous venovenous hemofiltration, continuous venovenous hemodialysis, or continuous venovenous hemodiafiltration) as there is no available data on dosing of FEP-ZID for those on CRRT at this time.
  25. Participants with a CrCl <15 mL/min will be included with the exception of: * Those on intermittent renal replacement therapy for a period shorter than 4 months prior to randomization * Diagnosis of acute kidney injury at study screening or randomization
  26. Screening serum total bilirubin >2 times the upper limit of normal (unless elevated indirect bilirubin due to known Gilbert's syndrome), or alanine aminotransferase ≥5 × upper limit of normal, or known to meet Child-Pugh class C criteria for liver insufficiency.
  27. On extracorporeal membrane oxygenation (ECMO) or expected to receive ECMO within 72 hours.
  28. Current neutropenia defined as <500 neutrophils/ mm3, or platelet count <50,000 per mL.
  29. Have received solid organ, stem cell, bone marrow transplant or had splenectomy.
  30. History of Clostridioides difficile-associated disease within 6 months prior to enrolment.
  31. Prior randomization in this study at any point, or use of any experimental drug or device within 30 days or 5 half-lives prior to enrollment.
  32. Has any condition or clinically significant abnormality or emergent surgery that, in the opinion of the investigator, is likely to interfere with optimal study participation, might confound the results of the study, or pose additional risk to the trial participant.
  33. Employed by the sponsor, investigator, or investigational site or is a first degree relative or spouse of a person employed by the sponsor or investigational site.

To główne kryteria z rejestru. Pełną listę i ostateczną decyzję o udziale ustala lekarz prowadzący badanie.

Zapytaj o udział w tym badaniu

Zadzwoń, a nasz doradca ds. badań sprawdzi z Tobą wstępnie kryteria i pomoże skontaktować się z ośrodkiem. Kwalifikację zawsze przeprowadza lekarz w ośrodku. Udział w badaniu jest bezpłatny i dobrowolny.

Wolisz, żebyśmy oddzwonili? Zostaw numer

O Twoim zdrowiu porozmawiamy dopiero przez telefon, po Twojej zgodzie. W formularzu nie podajesz takich informacji.

Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.

Inne badania: zapalenie płuc

W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza II

RSV: badanie fazy II leku S-337395

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

Badane leki: S-337395PolskaArgentynaBułgariaJaponiaRPATajwanUSAWietnam

Miasta: Chojncie, Chojnice, Ostrowiec Świętokrzyski, TarnówWiek: od 18 latSponsor: Shionogi B.V.

Wszystkie badania: zapalenie płuc

Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 9 listopada 2026.